-
Tytuł:
-
Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales.
-
Autorzy:
-
Perry-Duxbury M; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, The Netherlands. Electronic address: .
Asaria M; LSE Health, London School of Economics and Political Science, London, United Kingdom.
Lomas J; Centre of Health Economics, University of York, United Kingdom.
van Baal P; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, The Netherlands.
-
Źródło:
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2020 Aug; Vol. 23 (8), pp. 1027-1033. Date of Electronic Publication: 2020 Jul 19.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Jan./Feb. 2011- : New York : Elsevier
Original Publication: Malden, MA : Blackwell Science, c1998-
-
MeSH Terms:
-
Research Design*
Cost-Benefit Analysis/*methods
Health Expenditures/*statistics & numerical data
State Medicine/*organization & administration
Age Factors ; England ; Humans ; Life Expectancy ; Models, Econometric ; Quality-Adjusted Life Years ; Sex Factors ; State Medicine/economics ; Wales
-
Contributed Indexing:
-
Keywords: NICE; economic evaluation; future costs; unit costs
-
Entry Date(s):
-
Date Created: 20200824 Date Completed: 20201015 Latest Revision: 20201015
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.jval.2020.05.006
-
PMID:
-
32828214
-
Objectives: In many countries, future unrelated medical costs occurring during life-years gained are excluded from economic evaluation, and benefits of unrelated medical care are implicitly included, leading to life-extending interventions being disproportionately favored over quality of life-improving interventions. This article provides a standardized framework for the inclusion of future unrelated medical costs and demonstrates how this framework can be applied in England and Wales.
Methods: Data sources are combined to construct estimates of per-capita National Health Service spending by age, sex, and time to death, and a framework is developed for adjusting these estimates for costs of related diseases. Using survival curves from 3 empirical examples illustrates how our estimates for unrelated National Health Service spending can be used to include unrelated medical costs in cost-effectiveness analysis and the impact depending on age, life-years gained, and baseline costs of the target group.
Results: Our results show that including future unrelated medical costs is feasible and standardizable. Empirical examples show that this inclusion leads to an increase in the ICER of between 7% and 13%.
Conclusions: This article contributes to the methodology debate over unrelated costs and how to systematically include them in economic evaluation. Results show that it is both important and possible to include future unrelated medical costs.
(Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.)
